Feature|Videos|November 16, 2026

Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis

Mark Lebwohl, MD, discusses monitoring needs for TYK2 inhibitors and choosing among oral and injectable therapies for psoriasis.

Mark Lebwohl, MD, dermatologist, dean for clinical therapeutics at the Icahn School of Medicine at Mount Sinai, and chairman emeritus of the department of dermatology at Mount Sinai, addressed expected FDA requirements for TYK2 inhibitors in psoriasis and how he weighs oral and injectable options in a recent Dermatology Times Expert Perspectives custom video series. He also described a growing set of choices for patients.

Anticipated Monitoring Requirements for TYK2 Inhibitors

Lebwohl noted the agency has not yet defined requirements for the newer agents. The deucravacitinib package insert includes a discussion of tuberculosis screening, and he expects the FDA to require it again. The same insert references liver and lipid measures, but labeling for the newer agents remains unknown.

“We don’t know what the FDA will require,” Lebwohl said.

He does not expect many of the laboratory tests used with JAK inhibitors to be affected by TYK2 inhibitors. He is unsure any of those tests will ever prove helpful. Experience with deucravacitinib has been excellent, he said.

“We’ve not seen an increase in any impact on any of the parameters checked with blood work,” Lebwohl said.

“So I don’t think monitoring will be an important part of this,” Lebwohl said.

Oral and Injectable Options Beyond Apremilast

Lebwohl said the newer oral TYK2 inhibitors and icotrokinra have all shown superiority to apremilast or deucravacitinib. Deucravacitinib, in turn, showed superiority to apremilast. He considers these drugs more powerful, and he discusses a newer oral or an injectable biologic with patients.

Selecting IL-17 and IL-23 Blockers

IL-17 and IL-23 blockers appear highly effective in this population, Lebwohl said. For very severe disease, he is often inclined to use the fastest drugs available, which tend to be IL-17 blockers. Psoriatic arthritis also points him toward this class.

“I’ll often be inclined to use an IL-17 blocker because they do work fairly well and quickly for psoriatic arthritis,” Lebwohl said.

For patients who dislike injections, or who lack arthritis and want a convenient schedule, he often chooses IL-23 blockers, given as infrequently as every 2 or 3 months. Those patients are also offered an oral option such as icotrokinra, an IL-23 receptor blocker, or a TYK2 inhibitor. The newer TYK2 inhibitors appear just as effective as icotrokinra, he said.

More Choices for Patients With Psoriasis

“Having more choices to treat psoriasis is always better,” Lebwohl said. Patients who prefer to avoid injections do not need to receive them, and options exist for those wanting fast results or few doses.

“It is uncommon for me to not be able to successfully treat a psoriasis patient, thanks to all of these options,” Lebwohl said.


Related to this article